Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 4,636 matching trials from the live ClinicalTrials.gov search.
Completed Phase 1 Interventional Accepts healthy volunteers

Oral Remimazolam With and Without Alcohol in Healthy Female Subjects

NCT04113343
Conditions
Safety Issues
Interventions
Remimazolam, Alcohol
Drug · Other
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
21 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Fever
Interventions
Ibuprofen 250 mg / Acetaminophen 500 mg, Ibuprofen 250 mg, Acetaminophen 500 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Fresno, California + 24 more
Conditions
Achondroplasia
Interventions
Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
0 Years to 32 Months
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Oakland, California • Baltimore, Maryland • Madison, Wisconsin
Completed Phase 4 Interventional Accepts healthy volunteers

FLU-VACS Comparative Study in Adults

NCT00133523
Conditions
Influenza
Interventions
Cold-adapted live attenuated influenza virus vaccine, trivalent, Placebo, Trivalent inactivated influenza vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
2,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
6
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Livonia, Michigan + 2 more
Conditions
Schizophrenia
Interventions
AMG 579, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Conditions
Cytomegalovirus Infections
Interventions
AVX601, Placebo
Biological
Lead sponsor
AlphaVax, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers

NCT02834741
Conditions
Healthy Volunteers
Interventions
NYX-2925
Drug
Lead sponsor
Aptinyx
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Terminated Phase 1 Interventional Accepts healthy volunteers

Gastric Gluten-Degradation Activity of PvP001

NCT03594331
Conditions
Digestive System Disease
Interventions
Low-dose PvP001, Medium-dose PvP001, High-dose PvP001, Placebo
Drug
Lead sponsor
Danielle Kim Turgeon
Other
Eligibility
18 Years to 64 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Rheumatoid Arthritis
Interventions
FB704A, Placebo
Drug
Lead sponsor
Fountain Biopharma Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions
TNX-832, Placebo
Biological · Drug
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • St Louis, Missouri + 3 more
Conditions
Healthy
Interventions
VBY-036, Placebo
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Escalating Study of DAS181 in Adults

NCT00527865
Conditions
Influenza
Interventions
DAS181, Placebo
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Miramar, Florida
Not listed Phase 4 Interventional Accepts healthy volunteers

Endothelial Derived Hyperpolarization Factor and Vascular Control

NCT05176379
Conditions
Healthy
Interventions
Fluconazole 150 mg
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Norman, Oklahoma
Conditions
Acute Pain
Interventions
Wafermine, Oxycodone, Placebo
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota
Active, not recruiting Early Phase 1 Interventional

Diclofenac as a KMO Inhibitor

NCT06029296
Conditions
Alcohol Use Disorder
Interventions
Diclofenac, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Catonsville, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole

NCT02234570
Conditions
Neurocysticercosis
Interventions
Oxfendazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Iowa City, Iowa
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-510 in Healthy Adults

NCT04731922
Conditions
Healthy Participants
Interventions
TAK-510, TAK-510 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Conditions
Diabetes Mellitus, Obesity
Interventions
Trodusquemine (MSI-1436)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Infection Prophylaxis
Interventions
SAR279356, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Jacksonville, Florida + 3 more
Conditions
Crohn Disease
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,092 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
64
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 51 more
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Aerolized Hydroxychloroquine Sulfate, Placebo
Drug · Other
Lead sponsor
Pulmoquine Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
methylphenidate, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
21 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 1994
U.S. locations
1
States / cities
Salt Lake City, Utah